Emgality Global Sales in 2023
Global sales figures for Emgality in 2023 are not publicly available as of the latest reporting periods. Drug sales data is typically released quarterly and annually by pharmaceutical companies.
When Will Emgality Sales Data Be Available?
Specific sales figures for Emgality for the full year 2023 are generally reported by its manufacturer, Eli Lilly and Company, in their annual financial reports. These reports are usually released in the first quarter of the following year. For the most up-to-date information on Emgality's financial performance, it is advisable to consult Eli Lilly's official investor relations publications.
What Are Emgality's Indications?
Emgality is approved for the preventive treatment of episodic migraine in adults [1]. It is also indicated for the acute treatment of migraine with or without aura in adults [1].
How Does Emgality Work?
Emgality is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. By blocking the action of CGRP, a molecule that is thought to play a role in migraine, Emgality helps to reduce migraine frequency and severity [1].
Emgality Patent and Exclusivity Information
Understanding the patent and exclusivity landscape for Emgality is crucial for its market dynamics. Patent information and expiration dates are tracked to anticipate market entry for generic or biosimilar competitors. Detailed patent timelines and exclusivity periods for Emgality can be found on resources like DrugPatentWatch.com [2].
Competitors in the Migraine Treatment Market
The market for migraine treatments is competitive, with several other drugs available. These include other CGRP inhibitors, as well as older classes of migraine medications. Competitors to Emgality include other CGRP monoclonal antibodies and small molecule CGRP receptor antagonists, as well as triptans and gepants.
Eli Lilly and Company's Role
Eli Lilly and Company is the pharmaceutical company that developed and markets Emgality. As a major player in the pharmaceutical industry, Eli Lilly's portfolio includes a range of medications across various therapeutic areas.
Clinical Data on Emgality
Clinical trials have demonstrated Emgality's efficacy and safety in patients with episodic and chronic migraine. Key clinical data reports are available through regulatory agencies and scientific publications, detailing its effectiveness in reducing monthly migraine days and acute treatment success rates.
Patient Considerations for Emgality
Patients considering Emgality should discuss potential side effects, efficacy for their specific migraine type, and administration with their healthcare provider. Common side effects can include injection site reactions and nasopharyngitis.
Sources
1. Eli Lilly and Company - Emgality Prescribing Information
2. DrugPatentWatch.com